CERo Therapeutics Inc. (CERO)
NASDAQ: CERO
· Real-Time Price · USD
5.38
0.00 (0.00%)
At close: Sep 26, 2025, 3:59 PM
5.02
-6.69%
After-hours: Sep 26, 2025, 07:55 PM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors.
The company is based in South San Francisco, California.
CERo Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Christopher B. Ehrlich |
Contact Details
Address: 201 Haskins Way South San Francisco, California United States | |
| Website | https://www.cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 71902K402 |
| ISIN Number | US71902K4022 |
| Employer ID | 87-1088814 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer & Chair |
| Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
| Dr. Lawrence Corey M.D. | Co-founder & Head of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2025 | 8-K | Current Report |
| Sep 05, 2025 | 424B3 | Filing |
| Sep 05, 2025 | 424B3 | Filing |
| Sep 05, 2025 | 8-K | Current Report |
| Sep 04, 2025 | 424B3 | Filing |
| Sep 04, 2025 | 424B3 | Filing |
| Sep 04, 2025 | 8-K | Current Report |
| Aug 22, 2025 | 424B3 | Filing |
| Aug 22, 2025 | 424B3 | Filing |
| Aug 22, 2025 | 10-Q | Quarterly Report |